This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2016 Jan 20;34(3):e9-12.

doi: 10.1200/JCO.2013.49.8543. Epub 2014 Apr 28.

Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine

Jeremy Force¹, Romil Saxena¹, Bryan P Schneider¹, Anna M Storniolo¹, George W Sledge Jr¹, Naga Chalasani¹, Raj Vuppalanchi²

Affiliations

Affiliations

¹ Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
² Indiana University School of Medicine, Indiana University Health, Indianapolis, IN rvuppala@iupui.edu.

PMID: 24778392
DOI: 10.1200/JCO.2013.49.8543

Case Reports

Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine

Jeremy Force et al. J Clin Oncol. 2016.

. 2016 Jan 20;34(3):e9-12.

doi: 10.1200/JCO.2013.49.8543. Epub 2014 Apr 28.

Authors

Jeremy Force¹, Romil Saxena¹, Bryan P Schneider¹, Anna M Storniolo¹, George W Sledge Jr¹, Naga Chalasani¹, Raj Vuppalanchi²

Affiliations

¹ Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
² Indiana University School of Medicine, Indiana University Health, Indianapolis, IN rvuppala@iupui.edu.

PMID: 24778392
DOI: 10.1200/JCO.2013.49.8543

No abstract available

PubMed Disclaimer

Similar articles

Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
Lepelley M, Allouchery M, Long J, Boucherle D, Ranchoup Y, Le Marc'Hadour F, Villier C, Sturm N. Lepelley M, et al. Ann Hepatol. 2018 Oct 16;17(6):1067-1071. doi: 10.5604/01.3001.0012.7207. Ann Hepatol. 2018. PMID: 30600283 Review.
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2013 Sep 16;55(1424):75-6. Med Lett Drugs Ther. 2013. PMID: 24043217 No abstract available.
Ado-trastuzumab emtansine approved for advanced breast cancer.
Traynor K. Traynor K. Am J Health Syst Pharm. 2013 Apr 1;70(7):562. doi: 10.2146/news130023. Am J Health Syst Pharm. 2013. PMID: 23515502 No abstract available.
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2013 Sep 16;55(1425):75-6. Med Lett Drugs Ther. 2013. PMID: 24662957 No abstract available.
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM, Boster BL, Barnett CM. Baron JM, et al. J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27. J Oncol Pharm Pract. 2015. PMID: 24682654 Review.

See all similar articles

Cited by

Hepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series.
O'Sullivan CC, Higgins AS, Alkurashi AK, Ahluwalia V, Taraba JL, McKie PM, Kamath PS, Iyer VN, Haddad TC. O'Sullivan CC, et al. Front Oncol. 2024 Oct 21;14:1434492. doi: 10.3389/fonc.2024.1434492. eCollection 2024. Front Oncol. 2024. PMID: 39497716 Free PMC article.
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.
Kosmin M, Makris A, Jawad N, Woolf D, Miles D, Padhani AR. Kosmin M, et al. Target Oncol. 2017 Apr;12(2):229-234. doi: 10.1007/s11523-017-0477-6. Target Oncol. 2017. PMID: 28110417
Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
Wolska-Washer A, Robak T. Wolska-Washer A, et al. Drug Saf. 2019 Feb;42(2):295-314. doi: 10.1007/s40264-018-0775-7. Drug Saf. 2019. PMID: 30649747 Free PMC article. Review.
Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement.
Jharap B, van Asseldonk DP, de Boer NK, Bedossa P, Diebold J, Jonker AM, Leteurtre E, Verheij J, Wendum D, Wrba F, Zondervan PE, Colombel JF, Reinisch W, Mulder CJ, Bloemena E, van Bodegraven AA; NRH-Pathology Investigators. Jharap B, et al. PLoS One. 2015 Jun 8;10(6):e0120299. doi: 10.1371/journal.pone.0120299. eCollection 2015. PLoS One. 2015. PMID: 26054009 Free PMC article.
Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer.
Fujii Y, Doi M, Tsukiyama N, Hattori Y, Ohya K, Shiroma N, Morio K, Morioka T, Aikata H, Shinozaki K, Chayama K. Fujii Y, et al. Int Cancer Conf J. 2019 Oct 24;9(1):18-23. doi: 10.1007/s13691-019-00392-4. eCollection 2020 Jan. Int Cancer Conf J. 2019. PMID: 31950012 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations